Sat. Mar 25th, 2023

NEW YORK, March 18, 2023 /PRNewswire/ — Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the therapy of palmar hyperhidrosis applying its patented microchannel technologies. DTX-024 is a very purified and clinically tested injectable neuromodulator derived from neurotoxins created by Clostridium botulinum.

Aquavit Logo (PRNewsfoto/Aquavit Pharmaceuticals, Inc.)

Alongside Aquavit’s biosimilar plan for its botulinum toxin, this will be the 1st in the planet, indicated for palmar hyperhidrosis, authorized by FDA.

Aquavit has been investing in proprietary delivery technologies and connected intellectual home for botulinum toxin. This is a strategic move that puts them ahead of the curve in the rapidly-expanding multi-billion-dollar botulinum toxin industry.

To proficiently execute the approach, Aquavit has lately bolstered its executive group with seasoned veterans from the sector and the academia.

Dr. David Crean, PhD, MBA has been named Chief Monetary Officer of Aquavit Holdings. He has purchase- and sell-side experience in mergers &amp acquisitions (M&ampA), partnering and investments inside the life sciences and healthcare sectors functioning inside strategic biopharmaceutical businesses, private equity, investment banking and venture capital. He commenced his profession inside biopharmaceutical businesses additional than 30 years ago, most notably at Allergan, an Abbvie Organization, exactly where he lead deal execution for each technologies, item, and organization acquisitions and divestitures across a broad variety of therapeutic regions and small business units like injectable and topical healthcare aesthetics, dermatology, neurology, and ophthalmology. He serves on numerous boards like each public and private businesses and has been awarded various recognitions like San Diego’s 500 Most Influential persons for the previous 4 years (2019 -2022), 2020 Best Believed Leaders by Axial, M&ampA Advisor of the Year in 2019, and the 2018 Healthcare Hero Award.

Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC.

Story continues

Dr. Churlsu Kwon, MD. PhD. MPH., has been named Chief Healthcare Officer. He is a educated neurosurgeon and neuroscientist who brings a wealth of expertise and understanding to scientific developments, drug improvement and approval, and new drug discovery. He holds his degrees from University of Oxford and Harvard Healthcare College and presently holds an academic position at Columbia Healthcare College.

With Aquavit’s confirmed track record of creating and launching international brands, such as AQUAGOLD®, the organization has demonstrated their potential to effectively bring revolutionary solutions to industry. With their deep understanding of botulinum toxin and substantial network of physicians, Aquavit is properly-positioned to make a substantial effect in the sector.

“The neurotoxin industry is expanding quickly, with growing demand for revolutionary solutions and customized therapy plans. There is presently no FDA approval for palmar hyperhidrosis and by means of our novel route of administration we will be capable to supply new options to meet the evolving desires of sufferers in pathologies that are really debilitating. The provision of access for this population is a step in the appropriate path towards enhancing their well being and properly-becoming. ” Churl-Su Kwon, CMO Aquavit.

About Aquavit
Aquavit is an revolutionary healthcare organization that supplies a complete variety of proprietary pharmaceutical, biotech and healthcare device technologies. Aquavit focuses on customized medicine to strengthen patients’ well being, maximize the efficiency of our healthcare neighborhood, and help the pharmacoeconomics of payers.



View original content material to download multimedia:

Supply Aquavit Holdings

By Editor